DOI : 10.1055/s-00000054

Pharmacopsychiatry

Issue 06 · Volume 21 · December 2011 DOI: 10.1055/s-002-22322

A0
Hegerl, U; Himmerich, H; Rupprecht, R: Editorial
A2
Adamczyk, M; Fulda, S; Pawlowski, M; Steiger, A; Holsboer, F; Friess, E: Robust and stable automatic detection of rapid-eye movements in REM sleep
A3
Ambree, O; Zlomuzica, A; Buschert, J; Rothermundt, M; Zhang, W; Arolt, V; Dere, E: Impaired water-maze performance and altered adult hippocampal neurogenesis in histamine H1-receptor knockout mice
A5
Büll, D; Sato, M; Burgmaier, W; Bettecken, T; Weber, M; Rein, T; Uhr, M; Schmidt, U: Searching for biomarkers in a historic sample of Amyotrophic Lateral Sclerosis – The Munich Historic Brain Bank Project
A6
Baars, MY; Reuter, M; Harro, J; Eensoo, D; Gallhofer, B; Müller, MJ; Netter, P: Platelet activity and genetics of MAO B: How do they relate to impulsivity and aggression?
A7
Beitinger, PA; Beitinger, ME; Wehrle, R; Steiger, A: Delay of gratification in narcolepsy
A11
Brenndörfer, J; Widner, R; Czibere, L; Wolf, C; Touma, C; Bettecken, R; Landgraf, R: Copy number variants in two mouse models of affective disorders
A13
Buschert, J; Steinbrink, J; Steinbeck, J; Rothermundt, M; Zhang, W; Arolt, V; Ambree, O: Effects of psychosocial stress on the behavior of S100B transgenic mice
A14
Buschert, VC; Giegling, I; Merensky, W; Jolk, S; Teipel, SJ; Hampel, H; Rujescu, D; Buerger, K: Long-term observation of a multicomponent cognitive intervention in amnestic mild cognitive impairment (aMCI)
A16
Cabanis, M; Krug, A; Pyka, M; Walter, H; Winterer, G; Müller, B; Wiedemann, G; Vogeley, K; Wittorf, A; Rapp, A; Klingberg, S; Kircher, T: Neural correlates of Cognitive Behavioural Therapy effects on positive symptoms in patients with schizophrenic disorders
A17
Chittka, T; Minkwitz, J; Thormann, J; Olbrich, S; Sander, C; Hegerl, U; Himmerich, H: Vigilance and personality: neuroticism and sensation seeking as important markers for emotional psychopathologies
A18
Costa, A; Riedel, M; Pogarell, O; Rubia, K; Reiser, M; Moeller, HJ; Meindl, T; Ettinger, U: Methylphenidate effects on neural activity during response inhibition in healthy humans
A19
Cuboni, S; Hoogeland, B; Hauger, B; Eder, M; Hausch, F: Development of a screening assay for the SLC6A15/B0AT2 transporter
A20
Czibere, L; Brehm, N; Naik, R; Hermann, L; Schmidt, U; Landgraf, R: Functional characterisation of single-nucleotide polymorphisms in the HAB/LAB mouse Tmem132d promoter
A21
Czibere, L; Bunck, M; Brehm, N; Salvamoser, J; Kessler, MS; Landgraf, R: Phenotypic and genetic characterization of a short-term selective breeding for anxiety-related behavior
A22
Devigny, C; Perez-Balderas, F; Hoogeland, B; Cuboni, S; Webb, K; Deussing, JM; Hausch, F: Biomimetic screening of class B G protein-coupled receptors
A28
Eberlein, CK; Buchholz, V; Rhein, M; Wilhelm, J; Kornhuber, J; de Zwaan, M; Bleich, S; Frieling, H: How the serotonin transporter gene (SLC6A4) shapes the phenotype in eating disorders: a role for genotype and promoter methylation
A29
Filiou, MD; Teplytska, L; Gormanns, P; Reckow, S; Zhang, Y; Frank, E; Kessler, MS; Nussbaumer, M; Maccarrone, G; Landgraf, R; Turck, CW: Anxiety and mitochondria: Insights from the -omics world
A30
Filiou, MD; Teplytska, L; Otte, DM; Yilmaz, Ö; Zimmer, A; Turck, CW: Proteomic alterations in G72/G30 transgenic mice
A31
PGC-Consortium, SGENE-Consortium; Friedl, M; Giegling, I; Hartmann, AM; Konnerth, H; Konte, B; Möller, HJ; Rujescu, D: Neuropsychological intermediate phenotypes as tools for genetic studies in schizophrenia
A32
A33
Gassen, NC; Han, Y; Wochnik, G; Holsboer, F; Rein, T: Functional impact of FKBP51 on cellular pathways
A34
PGC-Consortium, SGENE-Consortium; Giegling, I; Hartmann, AM; Friedl, M; Konnerth, H; Konte, B; Möller, HJ; Rujescu, D: Genome wide association study in schizophrenia and intermediate phenotypes
A35
PGC-Consortium, SGENE-Consortium; Giegling, I; Hartmann, AM; Konnerth, H; Konte, B; Friedl, M; Möller, HJ; Rujescu, D: Copy number variants in schizophrenia
A36
Giegling, I; Hartmann, AM; Schneider, B; Maurer, K; Möller, HJ; Rujescu, D: Genetics of suicidal behaviour
A37
Giese, M; Beck, J; Brand, S; Muheim, F; Hatzinger, M; Holsboer-Trachsler, E; Eckert, A: Increase of serum BDNF level in depressive patients identifies therapy response and correlates with mood improvement
A38
Gopalakrishnan, R; Kozany, C; Hoogeland, B; Bracher, A; Hausch, F: FKBP ligands
A40
Graf, H; Abler, B; Freudenmann, R; Beschoner, P; Schaeffeler, E; Spitzer, M; Schwab, M; Grön, G: Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers: a randomized, placebo-controlled fMRI-study
A41
Grimm, S; Scheidegger, M; Henning, A; Walter, M; Weigand, A; Böker, H; Bajbouj, M; Seifritz, E: Emotionalcognitive processing and brain metabolism after pharmacological challenge with ketamine
A42
Gruber, O; Diekhof, EK; Zvonik, K; Trost, S; Weber, K; Petrovic, A; Henseler, I; Zilles, D; Melcher, T; Keil, M; Dechent, P; Falkai, P: Multi-functional MRI studies of disordered brain circuits in schizophrenic and affective psychoses
A43
Grünblatt, E; Bartl, J; Hofmann, S; Borst, A; Riederer, P; Walitza, S: d/l threo-methylphenidate enantiomers influence on catecholaminergic enzyme activities
A47
Hadar, R; Götz, T; Klein, J; Rummel, J; Schneider, M; Morgenstern, R; Winter, C: Deep brain stimulation on schizophrenic symptoms in the WIN rat model of schizophrenia
A48
Haen, E; Köstlbacher, A; Bader, W; Greiner, C; Hader, A; Köber, R; Wenzel-Seifert, K; Wittmann, M; Dörfelt, A; Melchner, D; Outlaw, E; Brandl, R: The dose-related reference range – a new tool for therapeutic drug monitoring (TDM)
A49
Hahn, E; Hahn, C; Dettling, M; Güntürkün, O; Ta, T; Neuhaus, A: Smoking and double dissociation of prefrontal cognition in schizophrenia
A50
Hartmann, AM; Giegling, I; Genius, J; Schäfer, M; Drago, A; Dolžan, V; Stassen, HH; Serretti, A; Möller, HJ; Rujescu, D: Pharmacogenetics of antipsychotics: focus on the glutamatergic system
A51
Hartmann, J; Wagner, KV; Liebl, C; Wolf, M; Scharf, SH; Wang, XD; Hausch, F; Rein, T; Schmidt, U; Touma, C; Müller, MB; Schmidt, MV: The involvement of FKBP51 and FKBP52 in the behavioural and neuroendocrine effects of acute and chronic stress
A53
Haussleiter, IS; Emons, B; Hoffmann, K; Jendreyschak, J; Schramm, A; Schaub, M; Richter, S; Armgart, C; Illes, F; Juckel, G: Drug prescription patterns in psychiatric inpatients
A55
Hennings, JM; Kohli, MA; Czamara, D; Wolf, C; Domschke, K; Arolt, V; Baune, T; Horstmann, S; Brückl, T; Klengel, T; Menke, A; Müller-Myhsok, B; Ising, M; Uhr, M; Lucae, S: BDNF and NTRK2 polymorphisms and antidepressant treatment outcome
A56
Herrmann, L; Golub, Y; Henes, K; Ionescu, I; Büll, D; Holsboer, F; Wotjak, CW; Schmidt, U: Decreased expression of synaptic proteins in a mouse model of posttraumatic stress disorder
A58
Hoehn, D; Czisch, M; Spoormaker, VI; Schröter, M; Goya-Maldonado, R; Holsboer, F; Sämann, PG: Resting state network alterations in major Depression
A62
Kiefer, T; Renner, L; Genzel, L; Dresler, M; Pawlowski, M; Steiger, A: Menstrual cycle effects on sleep-dependent memory consolidation
A63
Kiem, SA; Andrade, KC; Hoehn, D; Goya-Maldonado, R; Spoormaker, VI; Holsboer, F; Czisch, M; Sämann, PG: Combined fMRI/EEG to map non-genomic effects of exogeneous cortisol
A64
Klein, J; Männer, A; Eberhardt, C; Baldassarri, J; Jähkel, M; Morgenstern, R; Winter, C: Mapping brain regions stimulation affects schizophrenia-like behaviour in the Polyl:C rat model of schizophrenia
A66
Koller, G; Rominger, A; La Fougère, C; Cumming, P; Bartenstein, P; Soyka, M; Pogarell, O: Striatal and extrastriatal dopamine D2 receptor availability as assessed by [18F]fallypride and PET in patients with alcohol use disorder
A67
Konrad, C; Kugel, H; Zwitserlood, P; Dannlowski, U; Pyka, M; Domschke, K; Arolt, V; Kircher, T; Schöning, S: Serotonin-transporter polymorphism modulates anterior cingulate cortex activation during working memory tasks – an fMRI study
A68
Konte, B; Giegling, I; Hartmann, AM; Genius, J; Konnerth, H; Möller, HJ; Rujescu, D: Genome wide association study on memory in schizophrenia patients and unaffected healthy volunteers
A71
Labermaier, C; Liebl, C; Scharf, SH; Sillaber, I; Binder, EB; Müller, MB: Epigenetic modifications determining variability in antidepressant response: beyond genetic association studies
A72
Lerche, K; Willem, M; Kleinknecht, K; Romberg, C; Konietzko, U; Nitsch, RM; Holsboer, F; Wurst, W; Wotjak, CT; Deussing, JM: Dissecting the role of Corticotropin-releasing hormone receptor type 1 in Alzheimer's Disease
A75
Maccarrone, G; Nischwitz, S; Deininger, SO; Hornung, J; König, FB; Stadelmann, C; Turck, CW; Weber, F: MALDI imaging – a new tool for mapping multiple sclerosis brain lesions
A76
Menke, A; Eichelkraut, A; Preis, L; Klengel, T; Rex-Haffner, M; Uhr, M; Holsboer, F; Binder, EB: Gender related differential response to dexamethasone in endocrine and immune measures in depressed patients and healthy controls
A77
Minkwitz, J; Chittka, T; Jödicke, J; Olbrich, S; Sander, C; Thormann, J; Hegerl, U; Himmerich, H: The influence of the prestimulus EEG-vigilance on the reaction time in an auditory go/no-go task
A81
Mutschler, J; Dirican, G; Funke, S; Grosshans, M; Mann, K; Kiefer, F; Diehl, A: Experienced acetaldehyde-reaction is not associated with improved treatment response in patients treated with disulfiram
A82
Nothdurfter, C; Tanasic, S; Di Benedetto, B; Uhr, M; Kessler, J; Wagner, EM; Gilling, K; Parsons, C; Rein, T; Holsboer, F; Rupprecht, R; Rammes, G: Impact of lipid raft integrity on GABAA receptor function and its modulation by benzodiazepines
A83
Onuoha, M; Outlaw, E; Dörfelt, A; Jahner, T; Melchner, D; Ekkehard, H: Determination of phenothiazine concentration in serum – The importance of a suitable column
A84
Ostad Haji, E; Tadic, A; Dragicevic, A; Müller, MJ; Boland, K; Rao, ML; Fric, M; Laux, G; Hiemke, C: Measuring psychopathology by HAMD and CGI ratings to guide antidepressant treatment under naturalistic conditions
A85
Painold, A; Holl, AK; Letmaier, M; Kapfhammer, HP: Pharmacological treatment of psychosis in multiple sclerosis
A87
Paulzen, M; Tauber, SC; Kirner-Veselinovic, A; Gründer, G: Cytochrom 2D6 polymorphism and its impact on a rational psychopharmacotherapy
A90
Pogarell, O; Koch, W; Karch, S; Segmiller, F; Juckel, G; Mulert, C; Leicht, G; Hegerl, U; Möller, HJ; LaFougère, C; Rominger, A: Effects of escitalopram on serotonin and dopamine transporter availabilities in patients with depression
A91
Rademacher, L; Spreckelmeyer, K; Krach, S; Prinz, S; Vernaleken, I; Gründer, G: Effects of smoking cessation on reward processing
A97
Scharf, SH; Liebl, C; Binder, EB; Schmidt, MV; Müller, MB: Expression and regulation of the Fkbp5 gene in the adult mouse brain
A98
Scheidegger, M; Henning, A; Walter, M; Fuchs, A; Krähenmann, R; Böker, H; Bösiger, P; Seifritz, E; Grimm, S: Acute ketamine administration modulates glutamatergic neurotransmission and functional brain activation in prefrontal cortex implications for major depression
A99
Schmechtig, A; Lees, J; Dawson, GR; Dourish, CT; Craig, KJ; Deakin, JFW; Wilkinson, L; Williams, SCR; Ettinger, U: Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy
A100
Schmidt, FM; Bruegel, M; Kratzsch, J; Strauß, M; Sander, C; Baum, P; Thiery, J; Hegerl, U; Schönknecht, P: Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls
A103
A105
Segmiller, F; Karch, S; Koch, W; Juckel, G; Mulert, C; Hegerl, U; Padberg, F; Pogarell, O: Neurochemical modulation of cortical information processing – P300 event related potential and striatal dopamine
A106
Segmiller, F; Karch, S; Merz, H; Koller, G; Hock, B; Henning-Fast, K; Cerovecki, A; Riedel, M; Pogarell, O: Executive functions in patients with ADHD: An EEG-examination
A107
Stepan, J; Dine, J; von Wolf, G; Zieglgänsberger, W; Holsboer, F; Eder, M: High-speed voltage-sensitive dye imaging of neuronal activity propagation through limbic brain networks in vitro
A108
Szesny, N; Brückl, T; Pfister, H; Hennings, JM; Klengel, T; Menke, A; Uhr, M; Lucae, S; Holsboer, F; Ising, M; Zihl, J: Effectiveness of a standardised cognitive training in depression and the interaction with HPA-axis regulation
A110
A111
Thum, A; Haag, A; Rösler, J; Jacobs, H; Hermsen, A; Huber, M; Knake, S; Rosenow, F; Oertel, WH; Hamer, HM: Verbal declarative memory and language lateralization in patients with major depression: A functional transcranial Doppler sonography (fTCD) study
A112
Unterecker, S; Deckert, J; Pfuhlmann, B: No influence of body weight on serum levels of antidepressants
A114
Veselinovic, T; Schorn, H; Vernaleken, I; Hiemke, C; Zernig, G; Gur, R; Gründer, G: Effects of antipsychotic treatment on psychopathology and motor symptoms in healthy volunteers
A116
Wagner, KV; Hartmann, J; Wang, XD; Liebl, C; Wolf, M; Scharf, SH; Kohl, C; Marinescu, D; Müller, MB; Schmidt, MV: The role of different Homer1 isoforms in acute and chronic social stress
A117
Walser, SM; Dedic, N; Touma, C; Floss, T; Wurst, W; Holsboer, F; Deussing, JM: TMEM132D – a putative cell adhesion molecule involved in panic disorder
A119
Wilhelm, J; Heberlein, A; Frieling, H; Kornhuber, J; Bleich, S; Hillemacher, T: Association of prolactin serum levels and severity of alcohol dependence and withdrawal symptoms
A121
Willenborg, B; Schmoller, A; Melchert, U; Scholand-Engler, HG; Jauch-Chara, K; Hohagen, F; Schweiger, U; Oltmanns, KM: Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects
A122
Wittmann, M; Köstlbacher, A; Hader, A; Köber, R; Haen, E: The impact of metabolic pathways to drug-drug interactions
A124
Yen, Y; Anderzhanova, E; Kleinknecht, K; Bunck, M; Micale, V; Landgraf, R; Wotjak, CT: Inbred low anxiety-related behavior (LAB) mice – a mouse model of attention-deficit hyperactivity disorder (ADHD)?
A126
Zimmermann, N; Zschocke, J; Perisic, T; Yu, S; Almeida, OF; Holsboer, F; Rein, T: Mechanistic aspects of cell type and drug specific inhibition of DNA methyltransferase 1
A127
Zunhammer, M; Busch, V; Franz, J; Haas, J; Eichhammer, P: Exploring the CNS effects of acupuncture needling with TMS